id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S13648 R52926 |
Chambers (Controls unexposed, disease free), 2022 | Elective termination of pregnancy (for social or medical reason) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) Matched |
1.00 [0.06;16.07] C excluded (control group) |
1/279 1/279 | 2 | 279 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13649 R52942 |
Chambers (Controls unexposed, sick), 2022 | Elective termination of pregnancy (for social or medical reason) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) Matched | 3.01 [0.12;74.23] C | 1/279 0/279 | 1 | 279 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13687 R53196 |
Leroux, 2015 | Elective termination | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) | 0.62 [0.02;15.60] C | 0/41 1/77 | 1 | 41 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13679 R53149 |
Diav-Citrin, 2013 | Elective termination of pregnancy | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) | 2.73 [0.95;7.83] C | 6/115 9/455 | 15 | 115 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 2.42 [0.93;6.29] | 17 | 435 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 13648